SPDR S&P Biotech ETF
414 hedge funds and large institutions have $5.13B invested in SPDR S&P Biotech ETF in 2018 Q1 according to their latest regulatory filings, with 69 funds opening new positions, 146 increasing their positions, 119 reducing their positions, and 45 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
414
Holders Change
+17
Holders Change %
+4.28%
% of All Funds
9.5%
Holding in Top 10
19
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+11.76%
% of All Funds
0.44%
New
69
Increased
146
Reduced
119
Closed
45
Calls
$691M
Puts
$1.62B
Net Calls
-$927M
Net Calls Change
+$383M
Top Buyers
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$453M |
| 2 |
Morgan Stanley
New York
|
+$182M |
| 3 |
Goldman Sachs
New York
|
+$156M |
| 4 |
Rafferty Asset Management
New York
|
+$121M |
| 5 |
CI
Clal Insurance
Tel-Aviv,
Israel
|
+$119M |
Top Sellers
| 1 |
AssetMark Inc
Concord,
California
|
-$70.3M |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$65.2M |
| 3 |
BNP Paribas Financial Markets
Paris,
France
|
-$46.7M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$22.2M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$18.6M |
